{"version":"1.0","provider_name":"GenSight Biologics","provider_url":"https:\/\/www.gensight-biologics.com\/fr\/","author_name":"jbenedicto","author_url":"https:\/\/www.gensight-biologics.com\/fr\/author\/jbenedicto\/","title":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2023 - GenSight Biologics","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"NDQEaH65P2\"><a href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/04\/17\/11811\/\">GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2023<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/04\/17\/11811\/embed\/#?secret=NDQEaH65P2\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2023\u00a0\u00bb &#8212; GenSight Biologics\" data-secret=\"NDQEaH65P2\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.gensight-biologics.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Paris, France, le 17 avril 2024, 19h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir d\u00e9pos\u00e9 son document d\u2019enregistrement universel (URD) 2023 en [&hellip;]"}